Cargando…

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy

Detalles Bibliográficos
Autores principales:	Friedman, David J, Young, Kristina, Baird, Jason R, Cottam, Benjamin, Savage, Talicia, Newell, Pippa, Kasiewicz, Melissa, Redmond, William, Curti, Brendan, Crocenzi, Todd, Gough, Michael J, Crittenden, Marka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292427/ http://dx.doi.org/10.1186/2051-1426-2-S3-P207

Ejemplares similares

The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor
por: Crittenden, Marka R., et al.
Publicado: (2013)

Expression of NF-κB p50 in Tumor Stroma Limits the Control of Tumors by Radiation Therapy
por: Crittenden, Marka R., et al.
Publicado: (2012)

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
por: Young, Kristina H., et al.
Publicado: (2016)

Improved efficacy of radiation in combination with TGFβ inhibition in a colorectal cancer mouse model
por: Young, Kristina H, et al.
Publicado: (2013)

Immune consequences of CT-guided radiation therapy of mouse mammary tumors
por: Gough, Michael J, et al.
Publicado: (2013)

Programmed cell death-1 blockade in combination with stereotactic radiation in an orthotopic mouse model of hepatocellular carcinoma
por: Friedman, David, et al.
Publicado: (2015)

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2013)

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013)

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy
por: Crittenden, Marka R., et al.
Publicado: (2016)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Tumor control by intravenous administration of STING ligand requires combination with precisely timed radiation therapy
por: Baird, Jason, et al.
Publicado: (2015)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
por: Sturgill, Elizabeth R., et al.
Publicado: (2021)

Circulating immune cells in patients with surgically resected nonfunctional pancreatic neuroendocrine tumors
por: Jutric, Zeljka, et al.
Publicado: (2015)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Intratumoral injection of STING ligand promotes abscopal effect
por: Baird, Jason R, et al.
Publicado: (2014)

Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma
por: Gunderson, Andrew J., et al.
Publicado: (2019)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

The Impact of the Myeloid Response to Radiation Therapy
por: Gough, Michael J., et al.
Publicado: (2013)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

STING expression and response to treatment with STING ligands in premalignant and malignant disease
por: Baird, Jason R., et al.
Publicado: (2017)

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease
por: Baird, Jason R., et al.
Publicado: (2018)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
por: Montler, Ryan, et al.
Publicado: (2016)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

The paradox of radiation and T cells in tumors
por: Gough, Michael J., et al.
Publicado: (2022)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
por: Duhen, Rebekka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_75uhentgjof17hijg3ss4j70ka